HB918

Provides relative to pharmaceutical costs (OR +$153,127 GF EX See Note)

Introduced·2/27/26
Ment Text

Louisiana HB918 mandates the Department of Health to develop a list of critical prescription drugs and report annually on drug prices and their.

Louisiana HB918 requires the Department of Health to create and maintain a list of critical prescription drugs, focusing on those with high costs relative to other states and overall development costs. The department must prepare an annual report analyzing prescription drug prices and identifying drugs with excessively high costs. The report can include recommendations to reduce drug costs while maintaining access and quality of care.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Health and Welfare Committee
Next
Committee decision

Sponsors

0
1
R
Democratic CaucusRepublican Caucus

History

Mar 9

House

Read by title, under the rules, referred to the Committee on Health and Welfare.

Feb 27

House

Prefiled.

Feb 27

House

Under the rules, provisionally referred to the Committee on Health and Welfare.